This little-known pharma stock can rally more than 60% in 2023, JPMorgan says
A promising treatment for acute leukemia makes Syndax Pharmaceuticals an attractive stock, JPMorgan said. Analyst Anupam Rama initiated coverage of Syndax with an overweight rating ahead of what could be significant new data on the company's cancer therapy called revumenib. "Our Overweight rating…#jpmorgan #rama #anupamrama #sndx #syndax #augment101 #michaelbloom (Source: Reuters: Health)
Source: Reuters: Health - January 4, 2023 Category: Consumer Health News Source Type: news
Gilead buys out rights to cancer therapy from Jounce for $67 million By Reuters
Gilead Sciences (NASDAQ: ) will buy all the remaining rights for an experimental cancer therapy, GS-1811, from Jounce Therapeutics (NASDAQ: ) for $67 million, the drugmaker said on Tuesday. The amended licensing deal will bolster Jounce's cash resources in a challenging market for biotech…#jounce #jouncetherapeutics #gs1811 #gilead (Source: Reuters: Health)
Source: Reuters: Health - December 28, 2022 Category: Consumer Health News Source Type: news
Lab Notes: Chimeron Bio names new CEO; Amicus Therapeutics gets positive opinion for rare disease therapy
This week's Philadelphia-area life sciences industry news includes a biotechnology firm naming a new CEO, positive study results on an experimental cancer therapy for another, progress on a potential treatment for a rare disorder for a third, and more.
Here is the roundup:
The Philadelphia biotechnology company developing self-amplifying RNA vaccines and therapeutics has named Kevin Heyeck as its new CEO.
He succeeds former chief executive Jolly Mazumdar, who departed the post earlier this month … (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 23, 2022 Category: American Health Authors: John George Source Type: news
PET tracer reveals dynamics of immunotherapy
Whole-body PET imaging can help clinicians visualize how patients may respon...Read more on AuntMinnie.comRelated Reading:
Immuno-PET reveals persistent HIV infection
PET tracer proves effective for assessing immunotherapy
Immuno-PET shows tumor response to therapy
Zr-89 immuno-PET could help predict cancer therapy outcomes
Immuno-PET tracer offers hope for early cancer treatment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - December 13, 2022 Category: Radiology Source Type: news
Malvern-based Galera shares rise on FDA filing for lead cancer therapy drug
Shares of Chester County biopharmaceutical company developing new cancer therapies opened up 9% Monday after filing its first new drug application with the Food and Drug Administration.
Galera Therapeutics (NASDAQ: GRTX) of Malvern is seeking approval for avasopasem as a treatment for radiotherapy-induced severe oral mucositis in patients with head and neck cancer.
There are no FDA-approved treatment for severe oral mucositis. The condition can result in patients developing painful ulcers in the … (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - December 12, 2022 Category: American Health Authors: John George Source Type: news
Experimental cancer therapy shows success in more than 70% of patients in global clinical trials
New York, NY (December 10, 2022) — A new therapy that makes the immune system kill bone marrow cancer cells was successful in as many as 73 percent of patients in two clinical trials, according to researchers from The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. The…#florida #usnewsworldreport #honorrollhospital #ash #ny #neurologyneurosurgery #geriatrics #journalnewenglandjournalofmedicine #twitter #ajaichari (Source: Reuters: Health)
Source: Reuters: Health - December 11, 2022 Category: Consumer Health News Source Type: news
New blood cancer therapy treats seven in 10 patients
An antibody infusion could be a game changer for people with persistent multiple myeloma, an aggressive blood cancer. The therapy was successful about 73 per cent of the time. (Source: the Mail online | Health)
Source: the Mail online | Health - December 10, 2022 Category: Consumer Health News Source Type: news
Phase III results show Roche's subcutaneous formulation of Tecentriq is comparable to intravenous Tecentriq and delivered in minutes
Administered under the skin, the subcutaneous formulation reduces time spent receiving treatment to approx. seven minutes, compared with 30-60 minutes for IV infusion1Roche has submitted data from the IMscin001 study to health authorities, seeking approval for the subcutaneous option across all approved indications of IVTecentriq If approved,Tecentriq would be Roche ’s fourth subcutaneous cancer therapy,2-4 helping to improve the treatment experience for patients. In addition, it could save resources for healthcare systems5-10Basel, 1 December 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new pivotal data ...
Source: Roche Investor Update - December 1, 2022 Category: Pharmaceuticals Source Type: news
What they are saying: PASTEUR Act can help fight antimicrobial resistance
Antimicrobial resistance (AMR) is a growing health crisis resulting in nearly 50,000 U.S. deaths each year and1.27 million globally on an annual basis – higher than HIV/AIDS and malaria. To slow and control continued AMR, we need a robust pipeline of novel products, and at the same time we need to ensure they are used only in a limited set of circumstances and in only the most necessary cases. Without new products to address the problem, AMR glo bally could take 10 million lives yearly by 2050. Countless modern medical advances that depend on antibiotics—such as routine surgery, cancer therapy and treatment of chronic ...
Source: The Catalyst - November 30, 2022 Category: Pharmaceuticals Tags: Antimicrobial Resistance Source Type: news
Donald Perkins obituary
Physicist who played a key role from the birth of particle physics in the 1940s to the discovery of the Higgs bosonThe particle physicist Donald Perkins, who has died aged 97, made seminal discoveries about the structure of the proton, and nuclear interactions at extreme energies, and first proposed the use of beams of pion particles in cancer therapy. His career spanned the birth of particle physics, as it emerged from studies of cosmic rays in the 1940s, through its maturation in the final decades of the last century, to the climactic discovery of theHiggs boson in the 21st. He played key roles throughout.When Perkins be...
Source: Guardian Unlimited Science - November 22, 2022 Category: Science Authors: Frank Close Tags: Particle physics Higgs boson People in science Cancer research University of Oxford Higher education Source Type: news
Haystack Oncology Launches with $56 Million in Series A Financing to Accelerate Adoption of Post-Op Cancer Detection Technology and Optimize Cancer Therapy Monitoring and Treatment
Liquid biopsy approach delivers unparalleled sensitivity and specificity for detection of low-frequency mutant molecules to see what others can't
Financing led by Catalio Capital Management
BALTIMORE, Md., Nov. 16, 2022 -- (Healthcare Sales & Marketi... Diagnostics, Oncology, Venture Capital Haystack Oncology, circulating tumor DNA, MRD test (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 16, 2022 Category: Pharmaceuticals Source Type: news
Researchers design treatment to protect bones during cancer therapy
Approximately 50% of all cancer patients receive radiation therapy — a treatment that uses electrically charged particles to kill cancer cells. Although radiotherapy beams are aimed directly at the tumor, surrounding healthy tissue can be damaged… (Source: NSF News)
Source: NSF News - November 9, 2022 Category: Science Authors: NSF Source Type: news
Sugar molecules as a target in cancer therapy
Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism can be neutralized.
The immune system is actually extremely well equipped to get rid of abnormal cells. (Source: World Pharma News)
Source: World Pharma News - November 7, 2022 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
AI recommendations lead to more diagnoses of low LVEF
Clinicians who follow artificial intelligence (AI) recommendations are twic...Read more on AuntMinnie.comRelated Reading:
Echocardiographers warned of interventional radiation risk
Cardiac CT poised to become an increasingly valuable tool
Automated volumetry on CTPA can spot pulmonary hypertension
Echo links low atrial function to dementia later in life
Echo algorithm can diagnose cardiac dysfunction from cancer therapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 3, 2022 Category: Radiology Source Type: news
AI recommendations lead to more diagnoses of low LVEF diagnoses
Clinicians who follow artificial intelligence (AI) recommendations are twic...Read more on AuntMinnie.comRelated Reading:
Echocardiographers warned of interventional radiation risk
Cardiac CT poised to become an increasingly valuable tool
Automated volumetry on CTPA can spot pulmonary hypertension
Echo links low atrial function to dementia later in life
Echo algorithm can diagnose cardiac dysfunction from cancer therapy (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - November 3, 2022 Category: Radiology Source Type: news
